Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study

Blood (2024) 144 (Supplement 1): 773.

https://doi.org/10.1182/blood-2024-201057

Published: 2024

Journal Articles

Epcoritamab Induces in Vitro-Derived Terminally Differentiated Exhausted T Cells to Kill B Cells

Daisy Lin, Vanessa Spires, Jeremy Gale, Nathan Cheadle, Tine Casneuf, Gregg Masters, Lisa Grimm, Omar Jabado, Tahamtan Ahmadi, Mark Fereshteh, Maria Jure-Kunkel, Andrew J. Steele, Jordan Blum

Blood (2024) 144 (Supplement 1): 2998.

https://doi.org/10.1182/blood-2024-208250

Published: 2024

Journal Articles

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial

Blood (2023) 142 (Supplement 2): LBA-1.

https://doi.org/10.1182/blood-2023-191911

Published: 2023

Journal Articles

Population Pharmacokinetics of Subcutaneous Epcoritamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Tommy Li, Leonid Gibiansky, Apurvasena Parikh, Marcel van der Linden, Kinjal Sanghavi, Matthew Putnins, Mariana Sacchi, Huaibao Feng, Tahamtan Ahmadi, Manish Gupta, Steven Xu

Blood (2023) 142 (Supplement 1): 4481.

https://doi.org/10.1182/blood-2023-179555

Published: 2023

Journal Articles

Preclinical Anti-Tumor Activity of Hexabody-CD38 in Patient-Derived B Cell Lymphoma and Acute Myeloid Leukemia Xenograft Models

Ida H Hiemstra, PhD, Maarten L Janmaat, PhD, Peter Boross, PhD, Jeroen van den Brakel, Wessel ten Hagen, Sanne van Dooremalen, Sieto Bosgra, PhD, Bart ECG De Goeij, PhD, Grietje Andringa, Laurens Kil, PhD, A Kate Sasser, PhD, Tahamtan Ahmadi, MD PhD, David Satijn, PhD, Esther CW Breij, PhD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-140313

Published: 2020

Journal Articles

Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-135874

Published: 2020

Journal Articles

First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody ® -CD3×CD20) in B-Cell Non-Hodgkin Lymphomas

Pieternella Lugtenburg, MD PhD, Rogier Mous, MD PhD, Michael Roost Clausen, Martine E.D. Chamuleau, Peter Johnson, MDFRCP, Kim Linton, PhD, Simon Rule, Roberto S Oliveri, MD PhD, Dena DeMarco, Ida H Hiemstra, PhD, Guang Chen, Ada Azaryan, Manish Gupta, Tahamtan Ahmadi, Martin Hutchings, MD PhD

Blood (2019) 134 (Supplement_1): 758.

https://doi.org/10.1182/blood-2019-121460

Published: 2019

Journal Articles

Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies

Bart ECG De Goeij, PhD, Maarten L Janmaat, PhD, Grietje Andringa, Laurens Kil, Berris Van Kessel, Kristine A. Frerichs, MD, Andreas Lingnau, Andreas Freidig, Tuna Mutis, MD PhD, A. Kate Sasser, Esther C. W. Breij, Niels W. C. J. Van De Donk, MD PhD, Tahamtan Ahmadi, David Satijn

Blood (2019) 134 (Supplement_1): 3106.

https://doi.org/10.1182/blood-2019-125788

Published: 2019

Journal Articles

Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)

Blood (2018) 132 (Supplement 1): LBA-2.

https://doi.org/10.1182/blood-2018-120737

Published: 2018

Journal Articles

Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (GEN503): Final Results of an Open-Label, Phase 1/2 Study

Torben Plesner, MD, Hendrik-Tobias Arkenau, Francesca Marianatal Gay, Monique C Minnema, Mario Boccadoro, Philippe Moreau, MDPhD, James D Cavenagh, Aurore Perrot, MD, Jacob Laubach, MD, Tahamtan Ahmadi, Carla de Boer, Diana Chen, Christopher Chiu, Jordan Schecter, Paul G Richardson, MD

Blood (2017) 130 (Supplement 1): 1828.

https://doi.org/10.1182/blood.V130.Suppl_1.1828.1828

Published: 2017

Journal Articles

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

Ajai Chari, Attaya Suvannasankha, Joseph W. Fay, Bertrand Arnulf, Jonathan L. Kaufman, Jainulabdeen J. Ifthikharuddin, Brendan M. Weiss, Amrita Krishnan, Suzanne Lentzsch, Raymond Comenzo, Jianping Wang, Kerri Nottage, Christopher Chiu, Nushmia Z. Khokhar, Tahamtan Ahmadi, Sagar Lonial

Blood (2017) 130 (8): 974–981.

https://doi.org/10.1182/blood-2017-05-785246

Published: 2017

Includes: Supplemental data

Journal Articles

Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

Saad Z Usmani, MD FACP, Hareth Nahi, Maria-Victoria Mateos, MD PhD, Henk M. Lokhorst, MD PhD, Ajai Chari, MD, Jonathan L. Kaufman, MD, Philippe Moreau, Albert Oriol, MD, Torben Plesner, Professor, Lotfi Benboubker, MD PhD, Peter Hellemans, MD, Tara Masterson, Pamela L Clemens, PhD, Tahamtan Ahmadi, MD, Kevin Liu, Jesús San-Miguel, MD PhD

Blood (2016) 128 (22): 1149.

https://doi.org/10.1182/blood.V128.22.1149.1149

Published: 2016

Journal Articles

High-Parameter Mass Cytometry (CyTOF) Evaluation of Relapsed/Refractory Multiple Myeloma (MM) Pts (Pts) Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action

Homer Adams, III, PhD, Frederik Stevenaert, Jakub Krejcik, Koen Van der Borght, Tineke Casneuf, Tina Smets, Jaime Bald, Yann Abraham, Hugo Ceulemans, Greet Vanhoof, Tahamtan Ahmadi, MD, Saad Z Usmani, MD, Torben Plesner, Professor, Sagar Lonial, MD FACP, Berris van Kessel-Welmers, Henk M. Lokhorst, MD PhD, Tuna Mutis, MD PhD, Niels W.C.J. van de Donk, MD PhD, A. Kate Sasser

Blood (2016) 128 (22): 4521.

https://doi.org/10.1182/blood.V128.22.4521.4521

Published: 2016

Journal Articles

Daratumumab in Combination with Lenalidomide Plus Dexamethasone Induces Clonality Increase and T-Cell Expansion: Results from a Phase 3 Randomized Study (POLLUX)

Christopher Chiu, PhD, Tineke Casneuf, Amy Axel, Andrew Lysaght, Jaime Bald, Nushmia Z Khokhar, Torben Plesner, Professor, Saad Z Usmani, MD FACP, Hartmut Goldschmidt, MD, Tahamtan Ahmadi, MD, Kenneth Chan, A. Kate Sasser

Blood (2016) 128 (22): 4531.

https://doi.org/10.1182/blood.V128.22.4531.4531

Published: 2016

Journal Articles

Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone

Hervé Avet-Loiseau, Tineke Casneuf, Christopher Chiu, PhD, Jacob P. Laubach, MD, Je-Jung Lee, Philippe Moreau, Torben Plesner, Professor, Hareth Nahi, Nushmia Z Khokhar, Ming Qi, Jordan Schecter, Victoria Carlton, PhD, Xiang Qin, Kevin Liu, Kaida Wu, MD PhD, Sen H. Zhuang, MD, PhD, Tahamtan Ahmadi, MD, A. Kate Sasser, PhD, Jesús San-Miguel, MD PhD

Blood (2016) 128 (22): 246.

https://doi.org/10.1182/blood.V128.22.246.246

Published: 2016

Journal Articles

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma

Blood (2016) 128 (14): 1821–1828.

https://doi.org/10.1182/blood-2016-07-726729

Published: 2016

Includes: Supplemental data

Journal Articles

Daratumumab depletes CD38 + immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

Jakub Krejcik, Tineke Casneuf, Inger S. Nijhof, Bie Verbist, Jaime Bald, Torben Plesner, Khaja Syed, Kevin Liu, Niels W. C. J. van de Donk, Brendan M. Weiss, Tahamtan Ahmadi, Henk M. Lokhorst, Tuna Mutis, A. Kate Sasser

Blood (2016) 128 (3): 384–394.

https://doi.org/10.1182/blood-2015-12-687749

Published: 2016

Includes: Supplemental data

Journal Articles

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

Saad Z. Usmani, Brendan M. Weiss, Torben Plesner, Nizar J. Bahlis, Andrew Belch, Sagar Lonial, Henk M. Lokhorst, Peter M. Voorhees, Paul G. Richardson, Ajai Chari, A. Kate Sasser, Amy Axel, Huaibao Feng, Clarissa M. Uhlar, Jianping Wang, Imran Khan, Tahamtan Ahmadi, Hareth Nahi

Blood (2016) 128 (1): 37–44.

https://doi.org/10.1182/blood-2016-03-705210

Published: 2016

Includes: Supplemental data

Journal Articles

Re-Challenging with Anti-CD38 Monotherapy in Triple-Refractory Multiple Myeloma Patients Is a Feasible and Safe Approach

Johan Lund, MD, Evren Alici, MD PhD, Michael Chrobok, MD, Astrid Gruber, MD PhD, Tahamtan Ahmadi, Imran Khan, Hareth Nahi

Blood (2015) 126 (23): 5366.

https://doi.org/10.1182/blood.V126.23.5366.5366

Published: 2015

Journal Articles

Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)

Torben Plesner, MD, Hendrik-Tobias Arkenau, Peter Gimsing, Jakub Krejcik, Charlotte Lemech, Monique C. Minnema, Ulrik Lassen, Jacob P. Laubach, MD, Antonio Palumbo, Steen Lisby, Linda Basse, Jianping Wang, A Kate Sasser, Mary E Guckert, Howard Yeh, Tahamtan Ahmadi, Henk M. Lokhorst, Paul G. Richardson

Blood (2015) 126 (23): 507.

https://doi.org/10.1182/blood.V126.23.507.507

Published: 2015

NARROW

Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study

Epcoritamab Induces in Vitro-Derived Terminally Differentiated Exhausted T Cells to Kill B Cells

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial

Population Pharmacokinetics of Subcutaneous Epcoritamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Preclinical Anti-Tumor Activity of Hexabody-CD38 in Patient-Derived B Cell Lymphoma and Acute Myeloid Leukemia Xenograft Models

Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody ® -CD3×CD20) in B-Cell Non-Hodgkin Lymphomas

Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies

Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)

Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (GEN503): Final Results of an Open-Label, Phase 1/2 Study

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

High-Parameter Mass Cytometry (CyTOF) Evaluation of Relapsed/Refractory Multiple Myeloma (MM) Pts (Pts) Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action

Daratumumab in Combination with Lenalidomide Plus Dexamethasone Induces Clonality Increase and T-Cell Expansion: Results from a Phase 3 Randomized Study (POLLUX)

Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma

Daratumumab depletes CD38 + immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

Re-Challenging with Anti-CD38 Monotherapy in Triple-Refractory Multiple Myeloma Patients Is a Feasible and Safe Approach

Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only